IN8bio (IN8bio) 3-Year EBITDA Growth Rate : -28.80% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IN8bio 3-Year EBITDA Growth Rate?

IN8bio's EBITDA per Share for the three months ended in Mar. 2024 was $-0.19.

During the past 3 years, the average EBITDA Per Share Growth Rate was -28.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of IN8bio was -28.80% per year. The lowest was -63.40% per year. And the median was -35.10% per year.

Competitive Comparison of IN8bio's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, IN8bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IN8bio's 3-Year EBITDA Growth Rate falls into.

IN8bio 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

IN8bio (NAS:INAB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

IN8bio 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of IN8bio's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IN8bio (IN8bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

6JH:Germany

Address

350 5th Avenue, Suite 5330, New York, NY, USA, 10118

Website

https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Executives

Jeremy R. Graff	director	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall	officer: Chief Financial Officer	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho	director, officer: President, CEO and CFO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l.	director, 10 percent owner	40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc	10 percent owner	10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb	officer: EVP and CSO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami	officer: Chief Medical Officer	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin	officer: Chief Operating Officer	IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118